Selinexor with azacitidine and venetoclax for new AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older) with newly diagnosed AML
- Your doctor says you are not a good candidate for intensive chemotherapy, or you refuse it
- You have either age 75+ or specific health issues that make intensive chemotherapy unsafe (such as heart, lung, or kidney problems, or lower activity level)
- Your liver and kidney tests meet the study limits (for example, enough kidney function and acceptable bilirubin/AST/ALT levels)
- You have not had prior AML treatment (except hydroxyurea for symptom control)
- You do not have certain infections or brain involvement from AML (no known HIV, active hepatitis B/C, or AML in the central nervous system)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like MDS, AML, or CMML, especially those who have leftover leukemia cells before a stem cell transplant. The goal is to see if this treatment can improve outcomes.
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
This trial is for people age 55 and older with high-risk acute myeloid leukemia (AML) who have already had a stem cell transplant. It tests a new combination of two drugs, Selinexor and Melphalan, given twice a week to help prevent the leukemia from coming back.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.